000 03034nam a22005295i 4500
001 978-3-319-78238-6
003 DE-He213
005 20210201191423.0
007 cr nn 008mamaa
008 180424s2018 gw | s |||| 0|eng d
020 _a9783319782386
_9978-3-319-78238-6
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
082 0 4 _a614.5999
_223
245 1 0 _aResistance to Ibritumomab in Lymphoma
_h[electronic resource] /
_cedited by Makoto Hosono, Jean-François Chatal.
250 _a1st ed. 2018.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2018.
300 _aXIII, 158 p. 18 illus., 14 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v18
500 _aAcceso multiusuario
505 0 _aClinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
520 _aThis volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
541 _fUABC ;
_cTemporal ;
_d01/01/2021-12/31/2023.
650 0 _aCancer research.
650 1 4 _aCancer Research.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B11001
700 1 _aHosono, Makoto.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aChatal, Jean-François.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783319782379
776 0 8 _iPrinted edition:
_z9783319782393
776 0 8 _iPrinted edition:
_z9783030086527
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v18
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-78238-6
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c243288
_d243287